Recombinant Human Ccl22 Protein，His

Ccl22, also known as chemokine (C-C motif) ligand 22, is a member of the CC chemokine family that plays a crucial role in immune responses by facilitating the migration of immune cells, particularly regulatory T cells, to sites of inflammation and tumors. Its expression is tightly regulated and is associated with various pathological conditions, including cancer, autoimmune diseases, and chronic inflammatory disorders. Research into Ccl22 has gained traction due to its potential as a biomarker for disease progression and prognosis, as well as its therapeutic implications in modulating immune responses. Recombinant Ccl22 protein has been developed for various applications, including studying its effects on T cell recruitment and function in vitro and in vivo. Understanding the signaling pathways and mechanisms by which Ccl22 influences immune cell behavior could offer insights into novel treatment strategies for diseases characterized by immune dysregulation. Moreover, the use of Ccl22 in experimental settings could enhance the design of immunotherapies that aim to improve immune system efficacy against tumors while minimizing adverse effects associated with overactive immune responses. As such, the study of recombinant Ccl22 protein not only advances basic immunological research but also holds promise for clinical applications in the realm of immunotherapy and regenerative medicine.